Cansino Biotech (06185) announced that the recombinant pneumococcal protein vaccine developed by the company obtained positive initial results in phase I (including phase Ia and phase Ib) clinical trials.
PBPV is a globally innovative pneumonia vaccine under development. Unlike the 23-valent pneumococcal polysaccharide vaccine and the 13-valent pneumococcal polysaccharide conjugate vaccine, it is not a serotype-specific vaccine. It mainly uses antigens based on pneumococcal surface protein A (pSpA, a highly conservative protein expressed by almost all pneumococci). Compared with PPV23 and PCV13 currently on the market, PBPV has a higher serum coverage rate (at least 98% coverage of pneumococcal strains). Under high coverage protection, the generation of “serotype substitution” can be effectively prevented. At the same time, compared to polysaccharide vaccines and conjugated vaccines, this product has a simpler production process and is easier to scale up and quality control.